iTeos to shut down operations after TIGIT setback and GSK exit

29 May 2025

US biotech iTeos Therapeutics (Nasdaq: ITOS) is preparing to wind down its operations and halt clinical work, as it looks to sell off assets and return value to investors following a major blow to its lead immunotherapy program.

The Massachusetts-based company said its board has opted to cease development and operational activities, and instead focus on monetizing its pipeline, including the ENT1 inhibitor EOS-984, anti-TREM2 antibody EOS-215, and a pre-clinical obesity program. The decision comes as part of a broader strategic review aimed at maximizing shareholder returns.

iTeos said it will now prioritize efforts to sell its intellectual property, supported by a strong financial base. As of the end of 2024, the company held $655 million in cash and investments, a sum that was expected to fund operations through 2027.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology